Virios Therapeutics, Inc. (NASDAQ:VIRI – Get Free Report)’s stock price fell 1.5% on Thursday . The stock traded as low as $5.82 and last traded at $5.96. 52,000 shares traded hands during trading, a decline of 95% from the average session volume of 1,049,645 shares. The stock had previously closed at $6.05.
Virios Therapeutics Stock Performance
The firm’s 50 day moving average is $7.52 and its 200-day moving average is $4.19. The stock has a market capitalization of $114.78 million, a price-to-earnings ratio of -22.07 and a beta of 1.58.
Virios Therapeutics Company Profile
Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.
Further Reading
- Five stocks we like better than Virios Therapeutics
- Where Do I Find 52-Week Highs and Lows?
- Penny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to Sell
- Differences Between Momentum Investing and Long Term Investing
- Top 3 Beverage Stocks Pouring Out Profits
- What is the S&P 500 and How It is Distinct from Other Indexes
- CarMax and Carvana: Steering the Used Car Market
Receive News & Ratings for Virios Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virios Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
